» Articles » PMID: 19336371

Patterns of Respiratory Disease During the First 2 Postnatal Weeks in Extremely Premature Infants

Overview
Journal Pediatrics
Specialty Pediatrics
Date 2009 Apr 2
PMID 19336371
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pulmonary disease among infants of <28 weeks' gestation (extremely low gestational age newborns) often has the following pattern: the infant starts out with little need for supplemental oxygen and ventilatory support in the first postnatal week but then has pulmonary deterioration in the second postnatal week, with an increased need for supplemental oxygen and respiratory support. We evaluated the antecedents and correlates of patterns of early lung disease, with particular emphasis on pulmonary deterioration, in a large cohort study (the Extremely Low Gestational Age Newborn [ELGAN] study).

Patients And Methods: We examined data collected prospectively on 1340 infants born between 2002 and 2004 at 23 to 27 completed weeks of gestation and who survived to 14 days. Pulmonary deterioration was defined as receipt of fraction of inspired oxygen < 0.23 on any day between days 3 and 7 and receipt of fraction of inspired oxygen > or = 0.25 on day 14.

Results: One fifth (20%) of the infants had consistently low fraction of inspired oxygen, approximately two fifths (38%) had pulmonary deterioration, and the remaining approximately two fifths (43%) had consistently high fraction of inspired oxygen (early and persistent lung dysfunction). Compared with infants who had consistently low fraction of inspired oxygen, infants who experienced pulmonary deterioration had lower gestational ages and lower birth weights, had higher scores for neonatal acute physiology, and received more intensive modes of respiratory support. Gender, multifetal pregnancy, cesarean delivery, antenatal steroids, chorioamnionitis, and funisitis were not associated with pulmonary deterioration. The incidence of chronic lung disease, defined as oxygen therapy at 36 weeks' postmenstrual age, was 17% in the consistently low fraction of inspired oxygen group, 51% in the pulmonary deterioration group, and 67% in the early and persistent pulmonary dysfunction group. The incidence of death in these 3 groups before 36 weeks' postmenstrual age was 1%, 3%, and 5%, respectively.

Conclusions: Nearly 40% of extremely low gestational age newborns experience pulmonary deterioration in the first 2 postnatal weeks, and half of these infants develop chronic lung disease. Indicators of developmental immaturity and illness severity were associated with both pulmonary deterioration and chronic lung disease. Studying the antecedents of pulmonary deterioration might provide new insights about chronic lung disease pathogenesis.

Citing Articles

Role of Myeloperoxidase, Oxidative Stress, and Inflammation in Bronchopulmonary Dysplasia.

Wu T, Jing X, Teng M, Pritchard Jr K, Day B, Naylor S Antioxidants (Basel). 2024; 13(8).

PMID: 39199135 PMC: 11351552. DOI: 10.3390/antiox13080889.


Clinical characteristics of bronchopulmonary dysplasia in very preterm infants.

Yang Y, He X, Zhang X, Chen P Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 48(10):1592-1601.

PMID: 38432888 PMC: 10929901. DOI: 10.11817/j.issn.1672-7347.2023.230192.


Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome.

Sibrecht G, Kearl C, Borys F, Morariu M, Bruschettini M, Soll R Cochrane Database Syst Rev. 2023; 10:CD013158.

PMID: 37882216 PMC: 10600963. DOI: 10.1002/14651858.CD013158.pub2.


Combining lung ultrasound and oscillatory mechanics for assessing lung disease in very preterm infants.

Rigotti C, Zannin E, Dellaca R, Ventura M Pediatr Res. 2023; 95(4):1022-1027.

PMID: 37857847 DOI: 10.1038/s41390-023-02829-2.


Genetic analysis of potential biomarkers and therapeutic targets associated with ferroptosis from bronchopulmonary dysplasia.

Ma X, Tao Z, Chen L, Duan S, Zhou G, Ma Y Medicine (Baltimore). 2023; 102(29):e34371.

PMID: 37478211 PMC: 10662800. DOI: 10.1097/MD.0000000000034371.


References
1.
Hecht J, Kliman H, Allred E, Pflueger S, Chang C, Doss B . Reference weights for placentas delivered before the 28th week of gestation. Placenta. 2007; 28(10):987-90. DOI: 10.1016/j.placenta.2007.04.009. View

2.
Choi C, Kim B, Koh Y, Choi J, Choi J . Clinical characteristics of chronic lung disease without preceding respiratory distress syndrome in preterm infants. Pediatr Int. 2005; 47(1):72-9. DOI: 10.1111/j.1442-200x.2004.01996.x. View

3.
Clyman R . Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr. 1996; 128(5 Pt 1):601-7. DOI: 10.1016/s0022-3476(96)80123-5. View

4.
Marshall D, Kotelchuck M, Young T, Bose C, Kruyer L, OShea T . Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics. 1999; 104(6):1345-50. DOI: 10.1542/peds.104.6.1345. View

5.
Fowlie P, Davis P . Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2003; 88(6):F464-6. PMC: 1763231. DOI: 10.1136/fn.88.6.f464. View